Vol 60, No 3 (2022)
Original paper
Published online: 2022-09-16

open access

Page views 4685
Article views/downloads 929
Get Citation

Connect on Social Media

Connect on Social Media

HDAC5 inhibits ovarian angiogenesis in dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome

Ying Wang1, Yu Wang2, Yao Chen2, Qianqian Gao2, Lihui Hou1, Xiaoling Feng1
Pubmed: 36124413
Folia Histochem Cytobiol 2022;60(3):260-270.

Abstract

Introduction. Abnormal ovarian angiogenesis is a common feature of polycystic ovary syndrome (PCOS), a typical endocrine disorder affecting women of reproductive age. Histone deacetylase 5 (HDAC5) has been documented as a suppressor of angiogenesis. The aim of this study was to explore the effect of HDAC5 on ovarian angiogenesis in a PCOS mouse model.
Material and methods. PCOS was induced in female C57BL/6 mice by 20-day administration of dehydroepiandrosterone (DHEA). HDAC5 was over-expressed in PCOS mice by corresponding adenovirus injection. In total, 120 mice were used in this study. Western-blotting, real-time PCR, hematoxylin and eosin staining, enzyme-linked immunosorbent assay (ELISA), immunohistochemical staining, flow cytometry, and co-immunoprecipitation were respectively used to evaluate the effect of HDAC5 on PCOS mice.
Results. PCOS ovaries showed a compensatory increase in HDAC5 expression, while HDAC5 over-expression alleviated abnormalities in ovarian morphology and serum hormone levels after PCOS modeling. HDAC5 inhibited ovarian angiogenesis in PCOS mice by regulating angiogenesis-related factors, such as VEGFA, platelet-derived growth factors B and D (PDGFB/D), and angiopoietins 1 and 2 (ANGPT1/2) and CD31. HDAC5 over-expression decreased levels of reactive oxygen species (ROS) and malondialdehyde, while promoting activities of catalase and superoxide dismutase in ovaries of PCOS mice, suggesting its suppressive effects on oxidative stress, an inducer of uncontrolled angiogenesis. Moreover, HDAC5 suppressed activation of angiogenesis-related HIF-1α/VEGFA/VEGFR2 signaling in PCOS ovaries partly via inhibiting VEGFR2 acetylation.
Conclusions. This study reveals the protective role of HDAC5 in PCOS by inhibiting ovarian angiogenesis and provides a molecular candidate for PCOS therapy in the future.

Article available in PDF format

View PDF Download PDF file

References

  1. Zhang F, Ma T, Cui P, et al. Diversity of the gut microbiota in dihydrotestosterone-induced PCOS rats and the pharmacologic effects of diane-35, probiotics, and berberine. Front Microbiol. 2019; 10: 175.
  2. Mu Y, Cheng D, Yin TL, et al. Vitamin D and polycystic ovary syndrome: a narrative review. Reprod Sci. 2021; 28(8): 2110–2117.
  3. Ali AT, Guidozzi F, Ali AT. Polycystic ovary syndrome and metabolic syndrome. Ceska Gynekol. 2015; 80(4): 279–289.
  4. Di Pietro M, Pascuali N, Parborell F, et al. Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. Endocrinology. 2015; 156(4): 1453–1463.
  5. Wei J, Zhao Y. MiR-185-5p protects against angiogenesis in polycystic ovary syndrome by targeting VEGFA. Front Pharmacol. 2020; 11: 1030.
  6. Tan BK, Adya R, Chen J, et al. Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res. 2009; 83(3): 566–574.
  7. Di Pietro M, Parborell F, Irusta G, et al. Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. Endocrinology. 2015; 156(4): 1453–1463.
  8. Xu Z, Jia K, Wang H, et al. METTL14-regulated PI3K/Akt signaling pathway via PTEN affects HDAC5-mediated epithelial-mesenchymal transition of renal tubular cells in diabetic kidney disease. Cell Death Dis. 2021; 12(1): 32.
  9. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002; 1(4): 287–299.
  10. Zhou Y, Jin X, Ma J, et al. HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer. Cancer Res. 2021; 81(6): 1486–1499.
  11. Huang Y, Tan M, Gosink M, et al. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res. 2002; 62(10): 2913–2922.
  12. Li B, Zhang L, Zhu L, et al. HDAC5 promotes intestinal sepsis via the Ghrelin/E2F1/NF-κB axis. FASEB J. 2021; 35(7): e21368.
  13. Urbich C, Rössig L, Kaluza D, et al. HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood. 2009; 113(22): 5669–5679.
  14. Kim YW, Byzova TV, et al. Oxidative stress in angiogenesis and vascular disease. Blood. 2014; 123(5): 625–631.
  15. Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev. 2016; 2016: 8589318.
  16. Hu T, Schreiter FC, Bagchi RA, et al. HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression. J Biol Chem. 2019; 294(21): 8640–8652.
  17. Shi L, Tian Z, Fu Q, et al. miR-217-regulated MEF2D-HDAC5/ND6 signaling pathway participates in the oxidative stress and inflammatory response after cerebral ischemia. Brain Res. 2020; 1739: 146835.
  18. Abramovich D, Irusta G, Bas D, et al. Angiopoietins/TIE2 system and VEGF are involved in ovarian function in a DHEA rat model of polycystic ovary syndrome. Endocrinology. 2012; 153(7): 3446–3456.
  19. Azhary JMK, Harada M, Kunitomi C, et al. Androgens increase accumulation of advanced glycation end products in granulosa cells by activating ER stress in PCOS. Endocrinology. 2020; 161(2).
  20. Luo J, Deng ZL, Luo X, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2007; 2(5): 1236–1247.
  21. Cardiff RD, Miller CH, Munn RJ. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc. 2014; 2014(6): 655–658.
  22. Reichard A, Asosingh K. Best practices for preparing a single cell suspension from solid tissues for flow cytometry. Cytometry A. 2019; 95(2): 219–226.
  23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402–408.
  24. Zecchin A, Pattarini L, Gutierrez MI, et al. Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity. J Mol Cell Biol. 2014; 6(2): 116–127.
  25. Emidio GDi, Placidi M, Rea F, et al. Methylglyoxal-Dependent glycative stress and deregulation of SIRT1 functional network in the ovary of PCOS mice. Cells. 2020; 9(1): 209.
  26. Lim M, Thompson JG, Dunning KR. HYPOXIA AND REPRODUCTIVE HEALTH: Hypoxia and ovarian function: follicle development, ovulation, oocyte maturation. Reproduction. 2021; 161(1): F33–F40.
  27. Zhang J, Bao Y, Zhou Xu, et al. Polycystic ovary syndrome and mitochondrial dysfunction. Reprod Biol Endocrinol. 2019; 17(1): 67.
  28. Tessaro I, Modina SC, Franciosi F, et al. Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome. J Ovarian Res. 2015; 8: 64.
  29. Di Pietro M, Scotti L, Irusta G, et al. Local administration of platelet-derived growth factor B (PDGFB) improves follicular development and ovarian angiogenesis in a rat model of Polycystic Ovary Syndrome. Mol Cell Endocrinol. 2016; 433: 47–55.
  30. Laddha AP, Kulkarni YA. VEGF and FGF-2: Promising targets for the treatment of respiratory disorders. Respir Med. 2019; 156: 33–46.
  31. Kamat BR, Brown LF, Manseau EJ, et al. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol. 1995; 146(1): 157–165.
  32. Pascuali N, Scotti L, Oubiña G, et al. Platelet-derived growth factor B restores vascular barrier integrity and diminishes permeability in ovarian hyperstimulation syndrome. Mol Hum Reprod. 2020; 26(8): 585–600.
  33. Scotti L, Parborell F, Irusta G, et al. Platelet-derived growth factor BB and DD and angiopoietin1 are altered in follicular fluid from polycystic ovary syndrome patients. Mol Reprod Dev. 2014; 81(8): 748–756.
  34. Hilali N, Vural M, Camuzcuoglu H, et al. Increased prolidase activity and oxidative stress in PCOS. Clin Endocrinol (Oxf). 2013; 79(1): 105–110.
  35. Ostadmohammadi V, Jamilian M, Bahmani F, et al. Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome. J Ovarian Res. 2019; 12(1): 5.
  36. Xian D, Song J, Yang L, et al. Emerging roles of redox-mediated angiogenesis and oxidative stress in dermatoses. Oxid Med Cell Longev. 2019; 2019: 2304018.
  37. Liang A, Huang L, Liu H, et al. Resveratrol improves follicular development of PCOS rats by regulating the glycolytic pathway. Mol Nutr Food Res. 2021; 65(24): e2100457.
  38. Bahramrezaie M, Amidi F, Aleyasin A, et al. Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial. J Assist Reprod Genet. 2019; 36(8): 1701–1712.
  39. Parma L, Peters HAB, Johansson ME, et al. Bis(maltolato)oxovanadium(IV) Induces Angiogenesis via Phosphorylation of VEGFR2. Int J Mol Sci. 2020; 21(13).
  40. Xue Y, Lian W, Zhi J, et al. HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer. Br J Cancer. 2019; 121(12): 1039–1049.
  41. Zhou Y, Jin X, Yu H, et al. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Theranostics. 2022; 12(5): 2080–2094.